Granulocyte-macrophage colony-stimulating factor: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Line 71: Line 71:
Sargramostim was approved by the US FDA in 1991 to accelerate white blood cell recovery following autologous [[bone marrow transplantation]] under the trade name Leukine, and passed through several hands, ending up with [[Genzyme]]<ref>{{cite web |url=http://www.pharmaceutical-technology.com/projects/berlex/ |title=Bayer Healthcare Pharmaceuticals Plant, Snohomish County, Washington State |author= |work= |publisher=pharmaceutical-technology.com |accessdate=12 November 2011}}</ref> which subsequently was acquired by [[Sanofi]]. Molgramostim was eventually co-developed and co-marketed by Novartis and Schering-Plough under the trade name Leucomax for use in helping white blood cell levels recover following chemotherapy, and in 2002 Novartis sold its rights to Schering-Plough.<ref>{{cite web|title=Press release: Novartis Oncology sharpens focus on key growth drivers|url=https://www.sec.gov/Archives/edgar/data/1114448/000091205702040732/a2092547z6-k.htm|publisher=Novartis via SEC Edgar|date=30 October 2002}}</ref><ref>{{cite web|title=Scientific Conclusions and Grounds for Amendment of the Summary of Product Characteristics Presented by the EMEA|url=http://ec.europa.eu/health/documents/community-register/2000/200006273658/anx_3658_en.pdf|publisher=EMA CPMP|date=27 June 2000}}</ref>
Sargramostim was approved by the US FDA in 1991 to accelerate white blood cell recovery following autologous [[bone marrow transplantation]] under the trade name Leukine, and passed through several hands, ending up with [[Genzyme]]<ref>{{cite web |url=http://www.pharmaceutical-technology.com/projects/berlex/ |title=Bayer Healthcare Pharmaceuticals Plant, Snohomish County, Washington State |author= |work= |publisher=pharmaceutical-technology.com |accessdate=12 November 2011}}</ref> which subsequently was acquired by [[Sanofi]]. Molgramostim was eventually co-developed and co-marketed by Novartis and Schering-Plough under the trade name Leucomax for use in helping white blood cell levels recover following chemotherapy, and in 2002 Novartis sold its rights to Schering-Plough.<ref>{{cite web|title=Press release: Novartis Oncology sharpens focus on key growth drivers|url=https://www.sec.gov/Archives/edgar/data/1114448/000091205702040732/a2092547z6-k.htm|publisher=Novartis via SEC Edgar|date=30 October 2002}}</ref><ref>{{cite web|title=Scientific Conclusions and Grounds for Amendment of the Summary of Product Characteristics Presented by the EMEA|url=http://ec.europa.eu/health/documents/community-register/2000/200006273658/anx_3658_en.pdf|publisher=EMA CPMP|date=27 June 2000}}</ref>


==Research directions===
==Research directions==


GM-CSF is found in high levels in joints with [[rheumatoid arthritis]] and blocking GM-CSF as a [[biological target]] may reduce the inflammation or damage. Some drugs (e.g. [[MOR103]]) are being developed to ''block'' GM-CSF.<ref name="pmid23448220">{{cite journal | vauthors = Deiß A, Brecht I, Haarmann A, Buttmann M | title = Treating multiple sclerosis with monoclonal antibodies: a 2013 update | journal = Expert Review of Neurotherapeutics | volume = 13 | issue = 3 | pages = 313–35 | date = Mar 2013 | pmid = 23448220 | doi = 10.1586/ern.13.17 }}</ref>
GM-CSF is found in high levels in joints with [[rheumatoid arthritis]] and blocking GM-CSF as a [[biological target]] may reduce the inflammation or damage. Some drugs (e.g. [[MOR103]]) are being developed to ''block'' GM-CSF.<ref name="pmid23448220">{{cite journal | vauthors = Deiß A, Brecht I, Haarmann A, Buttmann M | title = Treating multiple sclerosis with monoclonal antibodies: a 2013 update | journal = Expert Review of Neurotherapeutics | volume = 13 | issue = 3 | pages = 313–35 | date = Mar 2013 | pmid = 23448220 | doi = 10.1586/ern.13.17 }}</ref>

Revision as of 01:41, 3 April 2018

Not to be confused with granulocyte colony-stimulating factor or macrophage colony-stimulating factor.
CSF2
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesCSF2, GMCSF, colony stimulating factor 2, CSF
External IDsOMIM: 138960; MGI: 1339752; HomoloGene: 600; GeneCards: CSF2; OMA:CSF2 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

1437

12981

Ensembl

ENSG00000164400

ENSMUSG00000018916

UniProt

P04141

P01587

RefSeq (mRNA)

NM_000758

NM_009969

RefSeq (protein)

NP_000749

NP_034099

Location (UCSC)Chr 5: 132.07 – 132.08 MbChr 11: 54.14 – 54.14 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse
Granulocyte-macrophage colony-stimulating factor
three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM_CSF)
Identifiers
SymbolGM_CSF
PfamPF01109
Pfam clanCL0053
InterProIPR000773
PROSITEPDOC00584
SCOP22gmf / SCOPe / SUPFAM
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
Granulocyte-macrophage colony-stimulating factor
Clinical data
ATC code
Identifiers
  • Human granulocyte macrophage colony stimulating factor
CAS Number
DrugBank
ChemSpider
  • none
Chemical and physical data
FormulaC639H1006N168O196S8
Molar mass14434.5 g/mol g·mol−1
 ☒NcheckY (what is this?)  (verify)

Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as colony-stimulating factor 2 (CSF2), is a monomeric glycoprotein secreted by macrophages, T cells, mast cells, natural killer cells, endothelial cells and fibroblasts that functions as a cytokine. The pharmaceutical analogs of naturally occurring GM-CSF are called sargramostim and molgramostim.

Unlike granulocyte colony-stimulating factor, which specifically promotes neutrophil proliferation and maturation, GM-CSF affects more cell types, especially macrophages and eosinophils.[5]

Function

GM-CSF is a monomeric glycoprotein that functions as a cytokine — it is a white blood cell growth factor.[6] GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exit the circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells. Thus, it is part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection.

GM-CSF also has some effects on mature cells of the immune system. These include, for example, inhibiting neutrophil migration and causing an alteration of the receptors expressed on the cells surface.[7]

GM-CSF signals via signal transducer and activator of transcription, STAT5.[8] In macrophages, it has also been shown to signal via STAT3. The cytokine activates macrophages to inhibit fungal survival. It induces deprivation in intracellular free zinc and increases production of reactive oxygen species that culminate in fungal zinc starvation and toxicity.[9] Thus, GM-CSF facilitates development of the immune system and promotes defense against infections.

GM-CSF also plays a role in embryonic development by functioning as an embryokine produced by reproductive tract.[10]

Genetics

The human gene has been localized in close proximity to the interleukin 3 gene within a T helper type 2-associated cytokine gene cluster at chromosome region 5q31, which is known to be associated with interstitial deletions in the 5q- syndrome and acute myelogenous leukemia. GM-CSF and IL-3 are separated by an insulator element and thus independently regulated.[11] Other genes in the cluster include those encoding interleukins 4, 5, and 13.[12]

Glycosylation

Human granulocyte-macrophage colony-stimulating factor is glycosylated in its mature form.

Medical use

GM-CSF was first cloned in the 1985, and soon afterwards three potential drug products were being made using recombinant DNA technology: molgramostim was made in Escherichia coli and is not glycosylated, sargramostim was made in yeast, has a leucine instead of proline at position 23 and is somewhat glyocylated, and regramostim was made in Chinese hamster ovary cells (CHO) and has more glycosylation than sargramostim. The amount of glycosylation affects how the body interacts with the drug and how the drug interacts with the body.[13]

At that time, Genetics Institute, Inc. was working on molgramostim,[14] Immunex was working on sargramostim (Leukine),[15] and Sandoz was working on regramostim.[16]

Sargramostim was approved by the US FDA in 1991 to accelerate white blood cell recovery following autologous bone marrow transplantation under the trade name Leukine, and passed through several hands, ending up with Genzyme[17] which subsequently was acquired by Sanofi. Molgramostim was eventually co-developed and co-marketed by Novartis and Schering-Plough under the trade name Leucomax for use in helping white blood cell levels recover following chemotherapy, and in 2002 Novartis sold its rights to Schering-Plough.[18][19]

Research directions

GM-CSF is found in high levels in joints with rheumatoid arthritis and blocking GM-CSF as a biological target may reduce the inflammation or damage. Some drugs (e.g. MOR103) are being developed to block GM-CSF.[20]

See also

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000164400 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000018916 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Root RK, Dale DC (1999). "Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients". The Journal of Infectious Diseases. 179 (Suppl 2): S342-352. doi:10.1086/513857. PMID 10081506.
  6. ^ Francisco-Cruz A, Aguilar-Santelises M, Ramos-Espinosa O, Mata-Espinosa D, Marquina-Castillo B, Barrios-Payan J, Hernandez-Pando R (Jan 2014). "Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor". Medical Oncology. 31 (1): 774. doi:10.1007/s12032-013-0774-6. PMID 24264600.
  7. ^ Gasson JC (Mar 1991). "Molecular physiology of granulocyte-macrophage colony-stimulating factor". Blood. 77 (6): 1131–45. PMID 2001448.
  8. ^ Voehringer D (Oct 2012). "Basophil modulation by cytokine instruction". European Journal of Immunology. 42 (10): 2544–50. doi:10.1002/eji.201142318. PMID 23042651.
  9. ^ Subramanian Vignesh K, Landero Figueroa JA, Porollo A, Caruso JA, Deepe GS (Oct 2013). "Granulocyte macrophage-colony stimulating factor induced Zn sequestration enhances macrophage superoxide and limits intracellular pathogen survival". Immunity. 39 (4): 697–710. doi:10.1016/j.immuni.2013.09.006. PMC 3841917. PMID 24138881.
  10. ^ Hansen PJ, Dobbs KB, Denicol AC (Sep 2014). "Programming of the preimplantation embryo by the embryokine colony stimulating factor 2". Animal Reproduction Science. 149 (1–2): 59–66. doi:10.1016/j.anireprosci.2014.05.017. PMID 24954585.
  11. ^ Bowers SR, Mirabella F, Calero-Nieto FJ, Valeaux S, Hadjur S, Baxter EW, Merkenschlager M, Cockerill PN (April 2009). "A conserved insulator that recruits CTCF and cohesin exists between the closely related but divergently regulated interleukin-3 and granulocyte-macrophage colony-stimulating factor genes". Molecular and Cellular Biology. 29 (7): 1682–1693. doi:10.1128/MCB.01411-08. PMID 2655614.
  12. ^ "Entrez Gene: CSF2 colony stimulating factor 2 (granulocyte-macrophage)".
  13. ^ Armitage, JO (15 December 1998). "Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor" (PDF). Blood. 92 (12): 4491–508. PMID 9845514.
  14. ^ "Molgramostim". AdisInsight. Retrieved 3 April 2018.
  15. ^ Staff (May 2008). "Back to the Future: Original Liquid Leukine® Coming Soon" (PDF). Oncology Business Review.
  16. ^ Hussein, AM; Ross, M; Vredenburgh, J; Meisenberg, B; Hars, V; Gilbert, C; Petros, WP; Coniglio, D; Kurtzberg, J; Rubin, P (November 1995). "Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy". European journal of haematology. 55 (5): 348–56. PMID 7493686.
  17. ^ "Bayer Healthcare Pharmaceuticals Plant, Snohomish County, Washington State". pharmaceutical-technology.com. Retrieved 12 November 2011.
  18. ^ "Press release: Novartis Oncology sharpens focus on key growth drivers". Novartis via SEC Edgar. 30 October 2002.
  19. ^ "Scientific Conclusions and Grounds for Amendment of the Summary of Product Characteristics Presented by the EMEA" (PDF). EMA CPMP. 27 June 2000.
  20. ^ Deiß A, Brecht I, Haarmann A, Buttmann M (Mar 2013). "Treating multiple sclerosis with monoclonal antibodies: a 2013 update". Expert Review of Neurotherapeutics. 13 (3): 313–35. doi:10.1586/ern.13.17. PMID 23448220.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Granulocyte-macrophage_colony-stimulating_factor&oldid=833923790"